Clinical Trial Update: Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dalotuzumab with cetuximab and irinotecan in metastatic colorectal cancer has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Dalotuzumab (dalotuzumab)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-12-28